Skip to content

GADOTERIC ACID

DRUG14 trials

Sponsors

Bayer AG, Novo Nordisk A/S, Eli Lilly & Co., Hospices Civils De Lyon, Assistance Publique Hopitaux De Paris

Conditions

Adverse Reaction to DrugAllergic Reaction to Contrast MediaArterial Occlusive DiseaseContrast enhancement in magnetic resonance imaging for assessment of central nervous system pathologyContrast enhancement in magnetic resonance imaging for assessment of non-central nervous system pathologyDiabetic Kidney DiseaseHeart Failure With Preserved Ejection Fraction (HFPEF)Huntington's disease

Phase 1

Phase 2

PLAQUE AND BRAIN INFLAMMATION IN SYMPTOMATIC CAROTID STENOSIS: ROLE OF THE FICOLIN-2 STATEMENT
Active, not recruitingCTIS2023-504573-20-00
Hospices Civils De Lyonstroke or transient ischemic attack
Start: 2023-10-09Target: 20Updated: 2026-01-21
QUANTITATIVE RENAL HYPERPOLARIZED [1-13C]PYRUVATE PERFUSION AND METABOLIC IMAGING IN DIABETIC KIDNEY DISEASE
RecruitingCTIS2023-508824-36-00
Aarhus UniversitetDiabetic Kidney Disease
Start: 2024-09-24Target: 27Updated: 2025-02-12
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
CompletedCTIS2023-503289-22-00
Eli Lilly & Co.Relapsing Multiple Sclerosis
Start: 2024-07-05End: 2025-12-15Target: 57Updated: 2026-01-09
Open-label extension study of long-term safety and efficacy of NNC6019-0001 in participants with transthyretin amyloid cardiomyopathy (ATTR CM)
Active, not recruitingCTIS2022-502605-15-00
Novo Nordisk A/SParticipants with transthyretin amyloid cardiomyopathy (ATTR CM)
Start: 2024-09-16Target: 58Updated: 2025-11-24
Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients.
CompletedNCT06731738
IC TARGETS ASHeart Failure With Preserved Ejection Fraction (HFPEF)
Start: 2024-11-22End: 2025-11-29Updated: 2026-01-08

Phase 3

Phase 4

Unknown Phase

Related Papers